LLS COVID-19 Response Program: Resources for Patients and Caregivers
The Leukemia & Lymphoma Society (LLS) hears from blood cancer patients and caregivers each day about the profound effects of the pandemic on their cancer care and daily lives, including questions about COVID-19 vaccines and how well they work for people with blood cancer.
From the beginning of the pandemic, LLS has been a leader in providing free education and support services to the people we serve, advocating for vaccination policies that consider and serve the unique needs of blood cancer patients. We also conduct our own COVID-19 research while also providing study support to institutions that produce important data on how the COVID-19 virus and vaccines affect people with blood cancer.
We encourage patients who have specific questions or concerns to speak directly with their doctors and care team. Our Information Specialists – highly trained oncology nurses, social workers and health educators who provide free, personalized assistance to patients, families and healthcare providers – are available to speak one-on-one with patients, caregivers and healthcare providers. Patients and caregivers can call (800) 955-4572 from Monday to Friday, 9 a.m. to 9 p.m. ET or visit www.lls.org/support/information-specialists
The Latest Information and Resources from LLS on COVID-19:
COVID-19 Vaccines: FAQs for patients and caregivers: updated frequently to provide the latest information on COVID-19, vaccines and other prevention strategies to help blood cancer patients—and everyone—protect themselves.
The LLS National Patient Registry, a project of the Michael J. Garil Patient Data Collective:
A unique opportunity for blood cancer patients to become citizen scientists by joining LLS to increase scientific knowledge about how COVID-19 and COVID-19 vaccines affect them
Study results
Late-breaking data reported at the American Society of Hematology on COVID-19 breakthrough infections in patients with blood cancer. (December 10, 2022)
Study from The Leukemia & Lymphoma Society Provides New Information on How Blood Cancer Patients Respond to COVID-19 Vaccines (September 8, 2022)
Largest Study to Date Demonstrates Most Blood Cancer Patients Benefit From a Third Primary Dose of mRNA COVID-19 Vaccine (December 13, 2021)
New study shows most blood cancer patients benefit from an additional COVID-19 vaccine dose (September 13, 2021)
COVID-19 vaccines provide protection to most blood cancer patients, but one in four have no detectable antibodies (July 22, 2021)
COVID-19 vaccine is safe among blood cancer patients (May 11, 2021)
Announcements
LLS National Patient Registry begins T-cell study in blood cancer patients (July 15, 2021)
LLS launches the National Patient Registry to answer COVID-19 questions for blood cancer patients (February 17, 2021)
Recent LLS Statements:
Study from The Leukemia & Lymphoma Society Provides New Information on How Blood Cancer Patients Respond to COVID-19 Vaccines (September 8, 2022)
LLS Statement on Federal Vaccination Strategy (September 10, 2021)
New COVID-19 staff safety policies at LLS (August 17, 2021)
Statement on FDA Authorization of Third Pfizer and Moderna COVID-19 Vaccine for People with Weakened Immune Systems (August 13, 2021)
Statement on Recent mRNA-based COVID-19 Vaccines Studies for Blood Cancer Patients (April 20, 2021)
Patient Support and Education Services:
Free, on-demand webcasts covering topics related to the COVID-19 pandemic.
Listen in to The Bloodline as experts and patients guide listeners in understanding diagnosis, treatment, and resources available to blood cancer patients.
March 21, 2022 episode: Protecting Patients: COVID and Vaccine Updates!
The LLS COVID-19 Response Program is supported in part by
LLS COVID-19 Response Education Programs are supported in part by
